Status:
COMPLETED
Intraprostatic Androgenicity in Relation to Circulating Levels of Hormones and Polymorphisms of Hormone-Related Genes: A Methodologic Study
Lead Sponsor:
National Cancer Institute (NCI)
Conditions:
Prostate
Eligibility:
MALE
18-100 years
Brief Summary
Although compelling evidence from laboratory studies suggests that androgens play a major role in prostate carcinogenesis, epidemiologic studies in humans (almost exclusively serologic studies) have b...
Detailed Description
Although androgens (male hormones) have been the central hypothesis in prostate cancer etiology for decades, epidemiologic studies in humans have not been able to confirm this hormonal hypothesis. Mos...
Eligibility Criteria
Inclusion
- INCLUSION CRITERIA:
- Subjects must be over age 18.
- Subjects must have a newly diagnosed prostate disease or condition.
- Subjects must not currently take hormones.
Exclusion
Key Trial Info
Start Date :
May 5 1999
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 15 2020
Estimated Enrollment :
553 Patients enrolled
Trial Details
Trial ID
NCT00342433
Start Date
May 5 1999
End Date
May 15 2020
Last Update
May 20 2020
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California, San Francisco
San Francisco, California, United States, 94143
2
Washington Hospital Center
Washington D.C., District of Columbia, United States, 20010
3
GW University Medical Center GW Hospital Center
Washington D.C., District of Columbia, United States, 20037
4
Doctors Community Hospital
Lanham, Maryland, United States